This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

This invention relates to oral veterinary compositions for combating ectoparasites and endoparasites in animals, comprising at least one systemically-acting active agent in combination with a pharmaceutically acceptable carrier. This invention also provides for improved methods for eradicating, controlling, and preventing parasite infections and infestations in an animal comprising administering the compositions of the invention to the animal in need thereof.

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.

The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

The present invention provides an egg-laying rate-improving agent for egg-laying hens, quails, or broiler breeders, the egg-laying rate-improving agent being characterized by comprising unheated cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.

The present invention provides an egg-laying rate-improving agent for egg-laying hens, quails, or broiler breeders, the egg-laying rate-improving agent being characterized by comprising unheated cashew nut shell liquid, heated cashew nut shell liquid, anacardic acid, cardanol, and/or cardol.

The invention relates to a dental device and an edible pet chew. The dental device comprises a dental protection composition containing at least one barrier material, at least one activated phosphatidylcholine, and, optionally, mineral oil. The edible pet chew comprises a dental protection composition, gelatin, and, optionally, one or more humectants, one or more preservatives, one or more structure-providing components, and one or more flavoring ingredients, wherein the dental protection composition contains at least one barrier material, at least one phosphatidylcholine, and, optionally, mineral oil.

The invention relates to a dental device and an edible pet chew. The dental device comprises a dental protection composition containing at least one barrier material, at least one activated phosphatidylcholine, and, optionally, mineral oil. The edible pet chew comprises a dental protection composition, gelatin, and, optionally, one or more humectants, one or more preservatives, one or more structure-providing components, and one or more flavoring ingredients, wherein the dental protection composition contains at least one barrier material, at least one phosphatidylcholine, and, optionally, mineral oil.

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.